# Iberia Pharmaceuticals India Limited: IPO analysis > Iberia Pharmaceuticals India Limited (CIN U21002DL2013PLC250040) has filed a Draft Red Herring Prospectus with SEBI for an IPO comprising a fresh issue of 64,75,560 shares. In FY26 it reported revenue of ₹97 Cr (+11.3% on FY25) and a net profit of ₹11 Cr. Promoters hold 96.4% before the IPO. Our earlier look-up of its claims found no medium or high concerns across 8 claims looked up. - Page: https://ipo.innerkore.com/in/company/U21002DL2013PLC250040/iberia-pharmaceuticals-india-limited/ - CIN: U21002DL2013PLC250040 - Last updated: 17 Sep 2026 ## Key facts - **Company:** Iberia Pharmaceuticals India Limited - **CIN:** U21002DL2013PLC250040 - **Filing stage:** DRHP - **Latest SEBI filing:** 17 Sep 2026 - **Listing on:** BSE, NSE - **Revenue FY26:** ₹97 Cr - **Revenue growth:** +11.3% - **Net profit FY26:** ₹11 Cr - **Revenue CAGR FY24 to FY26:** 18.0% - **Promoter holding (pre-IPO):** 96.4% - **Lead managers:** TURNAROUND CORPORATE ADVISORS PRIVATE LIMITED - **Registrar:** BIGSHARE SERVICES PRIVATE LIMITED - **Earlier look-up flags:** 0 high, 0 medium, 1 low ## Key signals (read from the filing; not investment advice) - **Growth** (look closer): 18% a year. Sales FY24 to FY26; latest year +11.3%. - **Profitability** (looks fine): 11.5% net margin. FY26; operating margin slipping. - **Debt** (looks fine): 0.37x equity. ₹19.3 crore borrowed at the end of FY26. - **Profit into cash** (looks fine): 99% of profit. Operations brought in ₹11 crore against ₹11.1 crore of profit in FY26. - **One-off income** (look closer): 11% of profit. Other and one-off income is 11% of pre-tax profit. - **Where the money goes** (looks fine): All new money. 100% is new shares issued by the company. 13% of the new money repays debt. - **Red flags** (looks fine): None serious. 8 claims looked up earlier: 0 high, 0 medium concern. ## Financial snapshot (₹ crore unless stated; consolidated) | | FY24 | FY25 | FY26 | |---|---:|---:|---:| | Sales | 69 | 87 | 97 | | Sales growth | – | 25.0% | 11.3% | | Operating profit | 11 | 22 | 17 | | Operating margin | 15.4% | 25.3% | 17.6% | | Net profit | 7.8 | 14 | 11 | | Net margin | 11.3% | 16.4% | 11.5% | | Net worth | 15 | 40 | 52 | | Borrowings | 11 | 15 | 19 | | Return on equity | 53.5% | 35.5% | 21.6% | ## Use of proceeds (fresh issue) - Capital expenditure towards the procurement of plant & machinery for the establishment of our manufacturing facility in Haryana, India: ₹35 crore - Repayment of all or a portion of certain outstanding borrowings availed by our Company: ₹12 crore - Branding and marketing expenses towards enhancing the awareness and visibility of our products and brand: ₹17 crore - Funding the working capital requirements of our Company: ₹31 crore - General Corporate Purposes (1): amount not fixed yet ## Claims looked up earlier - **LOW** (SubsidiaryPerformance): RRR Insolvency Service Experts LLP is an Indian LLP.. Search results indicate that RRR Insolvency Service Experts LLP is an entity associated with insolvency processes, as mentioned in an IPA ICAI Journal document. One result mentions a partner from this LLP and another shows a legal intern from the same LLP in New Delhi, India. - **NONE** (SubsidiaryPerformance): The company has the authority to make alterations, additions, or variations to the Issue in consultation with the BRLM or SEBI or other required authorities.. The provided search results do not contain information that directly corroborates or contradicts the claim regarding the company's authority to make alterations to the issue in consultation with BRLM or SEBI. The search results focus on financial performance, company details, and product launches, not regulatory authority. - **NONE** (SubsidiaryPerformance): Harmeet Kaur is registered with the Insolvency and Bankruptcy Board of India as an Insolvency Professional.. The provided web search results do not contain any information regarding whether Harmeet Kaur is registered with the Insolvency and Bankruptcy Board of India as an Insolvency Professional. Therefore, the claim cannot be corroborated or contradicted by the available sources. - **NONE** (SubsidiaryPerformance): Industry and market data used in this section has been derived from the "Industry Research Report on Pharmaceuticals and Dermatology Industry" dated July 31, 2026, prepared by CARE Analytics and Advisory Private Limited.. The search results do not contain any information that directly corroborates or contradicts the existence or details of an 'Industry Research Report on Pharmaceuticals and Dermatology Industry' dated July 31, 2026, prepared by CARE Analytics and Advisory Private Limited. - **NONE** (SubsidiaryPerformance): The company can seek approvals, clarifications, and exemptions from Stock Exchanges, SEBI, RBI, RoC, and other statutory/governmental authorities.. The search results provide financial and company overview information for Iberia Pharmaceuticals India, such as reported revenue and performance metrics. However, none of the provided snippets directly confirm or deny the company's ability to seek approvals, clarifications, or exemptions from various statutory and governmental authorities. - **NONE** (SubsidiaryPerformance): The Audit Committee is in compliance with Section 177 and other applicable provisions of the Companies Act and SEBI Listing Regulations.. The search results provide financial and company overview information for Iberia Pharmaceuticals India, but they do not contain any information that directly corroborates or contradicts the claim regarding the Audit Committee's compliance with Section 177 and SEBI Listing Regulations. - **NONE** (SubsidiaryPerformance): The company was originally incorporated on March 30, 2013 as ‘Satnam Medical Agencies Private Limited’.. The search results do not directly corroborate or contradict the claim that Iberia Pharmaceuticals India Limited was originally incorporated on March 30, 2013 as ‘Satnam Medical Agencies Private Limited’. The search results mention various entities like 'Satnam Exports (India) Ltd.' and 'Satnam Global Infraprojects Ltd.', which are separate entities or related but not explicitly confirming the incorporation date for the company in question. - **NONE** (SubsidiaryPerformance): The financial information was prepared in accordance with relevant provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 (ICDR Regulations).. The search results provide information about financial data (revenue, margins, EBITDA) related to Iberia Pharmaceuticals India IPO, but they do not directly confirm or deny the statement that the financial information was prepared in accordance with the SEBI (ICDR) Regulations. The results focus on reported figures and company details rather than the compliance statement itself. ## Common questions ### How big is the Iberia Pharmaceuticals India Limited IPO? Iberia Pharmaceuticals India Limited's IPO comprises a fresh issue of 64,75,560 shares, according to its Draft Red Herring Prospectus. The price band has not been announced yet: draft filings leave it blank and it is set in the Red Herring Prospectus. ### What are Iberia Pharmaceuticals India Limited's revenue and profit? Iberia Pharmaceuticals India Limited reported revenue from operations of ₹97 Cr in FY26, +11.3% versus FY25. Net profit was ₹11 Cr (FY25: ₹14 Cr). Revenue grew at a compound rate of 18.0% a year from FY24 to FY26. Figures are read from the DRHP, as printed there. ### How much do promoters own in Iberia Pharmaceuticals India Limited? Promoters hold 96.4% of Iberia Pharmaceuticals India Limited before the IPO. ### How will Iberia Pharmaceuticals India Limited use the IPO money? The fresh-issue proceeds are earmarked for: Capital expenditure towards the procurement of plant & machinery for the establishment of our manufacturing facility in Haryana, India (₹35 Cr); Repayment of all or a portion of certain outstanding borrowings availed by our Company (₹12 Cr); Branding and marketing expenses towards enhancing the awareness and visibility of our products and brand (₹17 Cr); Funding the working capital requirements of our Company (₹31 Cr); General Corporate Purposes (amount not fixed yet). ### What are the red flags in Iberia Pharmaceuticals India Limited's DRHP? Earlier, we looked up 8 claims from the filing on the open web (we no longer do this, since SEBI reviews the filing): 0 raised a high concern, 0 medium and 1 low. This is an automated screen, not a verdict; each finding links to its sources. ### What does Iberia Pharmaceuticals India Limited do? The IPO of Iberia Pharmaceuticals India Limited raises immediate red flags, pointing toward a concerning connection with insolvency processes. Search results link key figures in the process directly to RRR Insolvency Service Experts LLP, raising serious questions about the company's foundation. ### Who manages the Iberia Pharmaceuticals India Limited IPO? Book running lead managers: TURNAROUND CORPORATE ADVISORS PRIVATE LIMITED. Registrar to the offer: BIGSHARE SERVICES PRIVATE LIMITED. Shares are proposed to list on BSE and NSE. ### Where can I read the original Iberia Pharmaceuticals India Limited IPO documents? All 2 filings for Iberia Pharmaceuticals India Limited (DAP, DRHP) are listed on this page with links to the original PDFs on SEBI's website. Every page reference cites the exact page of the source document. ## Source documents - [IBERIA PHARMACEUTICALS INDIA LIMITED - DRHP](https://www.sebi.gov.in/sebi_data/commondocs/sep-2026/IBERIA%20PHARMACEUTICALS%20INDIA%20LIMITED_p.pdf) (Abridged prospectus (DAP), filed 17 Sep 2026) - [IBERIA PHARMACEUTICALS INDIA LIMITED - DRHP](https://www.sebi.gov.in/sebi_data/attachdocs/sep-2026/1789635115853.pdf) (Draft Red Herring Prospectus, filed 17 Sep 2026) --- Source: InnerKore IPO (https://ipo.innerkore.com/). Read from public SEBI filings by automated extraction; check the linked documents. Not investment advice.